Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GRI BioGRI -1.16%33 6-1 Month Momentum % is -40.24% as of Aug. 19, 2026. GuruFocus rates GRI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,378 Biotechnology companies, GRI Bio ranks worse than 80.62% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-19), GRI Bio's 6-1 Month Momentum % is -40.24%.
The industry rank for GRI Bio's 6-1 Month Momentum % or its related term are showing as below:
GRI's 6-1 Month Momentum % is ranked worse than 80.62% of 1378
companies
in the Biotechnology industry
Industry Median: -14.785
vs GRI: -40.24
GRI Bio (NAS:GRI) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
GRI Bio 6-1 Month Momentum % Related Terms
GRI vs ISCO, VRAX, SLXN: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, GRI Bio's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where GRI Bio's 6-1 Month Momentum % falls into.
GRI Bio (NAS:GRI) 6-1 Month Momentum % Calculation
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum %
=
( Price 1-month ago
/
Price 6-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI Bio (GRI) has a 6-1 Month Momentum % of -40.24% as of Aug. 19, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on GRI Bio and its competitors. According to the industry distribution chart, GRI Bio ranks #1111 out of 1378 companies in the Biotechnology industry, placing it in the top 80.6%.
Is GRI Bio's 6-1 Month Momentum % too high?
GRI Bio's current 6-1 Month Momentum % is -40.24%. Based on the distribution chart, GRI Bio ranks #1111 out of 1378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GRI Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does GRI Bio's 6-1 Month Momentum % compare to ISCO and VRAX?
According to the Biotechnology industry distribution chart, GRI Bio ranks #1111 out of 1378 companies for 6-1 Month Momentum %. This places GRI Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on GRI Bio and its competitors. GRI Bio's current 6-1 Month Momentum % is -40.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRI Bio stock overvalued right now?
GRI Bio (GRI) has a current 6-1 Month Momentum % of -40.24%. The current 6-1 Month Momentum % is -40.24%. GRI Bio's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For GRI Bio (GRI), the current 6-1 Month Momentum % is -40.24% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
33GF Score
Get the complete analysis for GRI
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRI has been successfully added to your 
